BioCentury
ARTICLE | Company News

Rademacher, SR Pharma deal

April 2, 2001 7:00 AM UTC

The companies set up a 50-50 joint venture to explore the therapeutic applications of bacterial inositol phosphoglycans (IPGs), which are hormone and growth factor second messengers. Potential disease...